Repligen Corp (NASDAQ: RGEN) kicked off on Friday, down -3.47% from the previous trading day, before settling in for the closing price of $122.32. Over the past 52 weeks, RGEN has traded in a range of $102.96-$182.52.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 18.61% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 6.04%. With a float of $53.12 million, this company’s outstanding shares have now reached $56.18 million.
In an organization with 1778 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 42.72%, operating margin of -5.62%, and the pretax margin is -4.12%.
Repligen Corp (RGEN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Repligen Corp is 5.46%, while institutional ownership is 102.46%. The most recent insider transaction that took place on May 15 ’25, was worth 3,271,688. In this transaction Director of this company sold 26,447 shares at a rate of $123.71, taking the stock ownership to the 109,854 shares. Before that another transaction happened on May 15 ’25, when Company’s Director proposed sale 26,447 for $128.34, making the entire transaction worth $3,394,208.
Repligen Corp (RGEN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 6.04% per share during the next fiscal year.
Repligen Corp (NASDAQ: RGEN) Trading Performance Indicators
Take a look at Repligen Corp’s (RGEN) current performance indicators. Last quarter, stock had a quick ratio of 5.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.20. Likewise, its price to free cash flow for the trailing twelve months is 55.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.41, a number that is poised to hit 0.40 in the next quarter and is forecasted to reach 2.18 in one year’s time.
Technical Analysis of Repligen Corp (RGEN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.79 million. That was better than the volume of 0.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.39%. Additionally, its Average True Range was 6.01.
During the past 100 days, Repligen Corp’s (RGEN) raw stochastic average was set at 18.99%, which indicates a significant increase from 7.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.46% in the past 14 days, which was lower than the 59.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $129.81, while its 200-day Moving Average is $143.97. However, in the short run, Repligen Corp’s stock first resistance to watch stands at $120.93. Second resistance stands at $123.79. The third major resistance level sits at $125.70. If the price goes on to break the first support level at $116.16, it is likely to go to the next support level at $114.25. The third support level lies at $111.39 if the price breaches the second support level.
Repligen Corp (NASDAQ: RGEN) Key Stats
The company with the Market Capitalisation of 6.63 billion has total of 56,183K Shares Outstanding. Its annual sales at the moment are 634,440 K in contrast with the sum of -25,510 K annual income. Company’s last quarter sales were recorded 169,170 K and last quarter income was 5,830 K.
